Education
About Us
Working with TipRanks
Follow Us
Galapagos (GLPG)
NASDAQ:GLPG
Earnings Data
Report Date
May 06, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.15Last Year’s EPS
-2.67Same Quarter Last Year
Moderate Sell
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balances strong strategic positives — a ~EUR 3.0 billion cash position, a return to operating profit in 2025 (driven by a EUR 1,069 million deferred income release), a positive Phase II topline for GLPG3667 in dermatomyositis, a refreshed leadership team and an active business-development pipeline — against meaningful near-term headwinds including large one-time impairment and wind-down charges (EUR ~399.8 million impact), a year-over-year cash decline (~9.6%), and chunky restructuring and wind-down cash outflows expected in 2026 (EUR 125–175 million plus additional costs). The operating profit is largely non-recurring accounting-driven, and execution risk remains around BD activity, TYK2 pathway decisions, and restoring investor confidence. Overall, highlights slightly outweigh lowlights given the strong balance sheet, strategic clarity and positive clinical result, but material near-term costs and uncertainty temper the outlook.Company Guidance
Strong year-end cash position
Financial investments and cash & cash equivalents totaled approximately EUR 2,998 million at December 31, 2025 (c. EUR 3.0 billion), providing significant strategic flexibility for business development.
Return to operating profit (non-recurring driver)
Total operating profit from continuing operations of EUR 295.1 million in 2025 versus an operating loss of EUR 188.3 million in 2024 — a swing of EUR 483.4 million largely driven by the one-time release of deferred revenue related to the OLCA (EUR 1,069 million).
Release of deferred income (OLCA)
Recognition of EUR 1,069 million of remaining deferred income associated with the Gilead OLCA after assessing no remaining obligations, which materially improved 2025 operating profit; management noted no expected cash tax impact from this recognition.
Positive Phase II topline for GLPG3667 (TYK2) in dermatomyositis
GLPG3667 met the primary endpoint in the dermatomyositis Phase II study with statistically significant clinical benefit and meaningful improvement on secondary measures versus placebo; management is evaluating strategic options (including partnerships) to accelerate development.
Experienced new leadership and board refresh
New management team assembled with strong business development and deal expertise; five new board directors added with transaction, capital allocation and operating experience to execute the new strategic direction.
Focused, disciplined business-development strategy with Gilead collaboration
Company is prioritizing clinically de-risked opportunities (primarily immunology & inflammation and oncology), emphasizing disciplined capital allocation; Gilead remains a strategic partner that can potentially contribute to deal economics and development spend and thus extend the effective purchasing power beyond Galapagos' cash base.
Improved currency mix and interest yield rationale
Company increased USD exposure (now approximately 72% USD / 28% EUR of cash and financial investments) to align with expected BD activity and U.S. cost base and to capture higher dollar interest rates (management cited ~4% USD vs ~2% EUR yields).
Lowered wind-down restructuring range
One-time restructuring cash impact for 2026 reduced by EUR 25 million from the prior guidance range: new range EUR 125–175 million (previously EUR 150–200 million).
GLPG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GLPG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 23, 2026 | $33.87 | $34.36 | +1.45% |
Nov 05, 2025 | $29.89 | $31.20 | +4.38% |
Jul 23, 2025 | $33.29 | $30.85 | -7.33% |
Apr 23, 2025 | $25.50 | $26.49 | +3.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Galapagos (GLPG) report earnings?
Galapagos (GLPG) is schdueled to report earning on May 06, 2026, After Close (Confirmed).
What is Galapagos (GLPG) earnings time?
Galapagos (GLPG) earnings time is at May 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GLPG EPS forecast?
GLPG EPS forecast for the fiscal quarter 2026 (Q1) is -1.15.